Lek's medicines will continue to be available without copayment
The pharmaceutical company Lek submitted adjusted prices for its leading products to the Agency for Medicinal Products of the Republic of Slovenia (the Agency). This will make it possible for patients to continue using existing therapies without copayment. Without this move, as of November 1 of this year, patients would have had to pay for the added costs of drugs as established by the decrees of the Public Health Insurance Institute of the Republic of Slovenia- ZZZS.
As of November 1, 2003, in cases where more versions of an equivalent drug are available on the Slovenian market, the ZZZS will cover only the maximum allowed value of the cost of the drug. The allowed value will now equal the lowest existing price among the various comparable drugs. Lek adjusted its prices to accord with the list of comparable drugs available on the Slovenian market. The prices of Lek’s drugs will be able to meet the future costs of medical coverage within the terms of the patients’ health insurance policies.
These price corrections will allow patients to continue using existing therapies without the complications and confusion that might arise when switching to an equivalent drug.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
- * *
For additional information, please contact: + 386 1 580 22 43 Katarina Klemenc Dinjaški, Lek’s Corporate Communications